Cognitive Impairment in Parkinson's Disease

Cognitive impairment in Parkinson’s disease (PD) encompasses a spectrum of non-motor manifestations that range from subtle deficits in executive and visuospatial functions to overt dementia. Mild cognitive impairment in PD (PD-MCI) may arise early in the disease trajectory, often preceding or accompanying motor symptoms. Its heterogeneous profile reflects involvement of multiple neurotransmitter systems, including dopaminergic, cholinergic and noradrenergic circuits, as well as the deposition of pathological proteins such as α-synuclein, β-amyloid and tau. Clinically, PD-MCI carries an elevated risk of progression to Parkinson’s disease dementia (PDD), which affects up to 80 per cent of patients after 15–20 years of disease. The onset, severity and rate of cognitive decline vary widely among individuals, influenced by factors such as age at onset, educational attainment, genetic variants and comorbidities. Neuroimaging studies have revealed structural and functional alterations in frontostriatal and parietal networks, while neuropsychological assessments identify discrete cognitive phenotypes, including amnestic, dysexecutive and mixed subtypes. Early identification of patients at high risk of dementia conversion is critical for stratifying trial cohorts and tailoring interventions aimed at preserving cognitive function. Interdisciplinary approaches combining clinical assessment, biomarkers and advanced computational modelling are driving efforts to refine prognostic tools and to develop targeted therapies that may slow or prevent cognitive deterioration in PD.

Research from Nature Portfolio

Large-scale neuropsychological surveys have quantified the prevalence and heterogeneity of PD-MCI in community and clinic cohorts. One foundational study applied rigorous diagnostic criteria to an Australian sample and found that nearly two thirds of participants met criteria for PD-MCI at baseline, with multiple-domain impairment far more common than single-domain deficits. This work highlighted the predominance of amnestic and non-amnestic multi-domain profiles, underscoring the need for standardised subtyping to guide longitudinal studies. The findings emphasise that PD-MCI is not a unitary entity but comprises diverse cognitive at-risk profiles, each with distinct trajectories and potential therapeutic targets.

Cognitive Impairment in Parkinson's Disease publication trend

The graph below shows the total number of articles in cognitive impairment in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Mild cognitive impairment (PD-MCI): A prodromal stage of cognitive decline in Parkinson’s disease characterised by measurable deficits on neuropsychological tests without significant functional impairment.

Parkinson’s disease dementia (PDD): A late-stage cognitive disorder in PD featuring global impairment in attention, memory and executive function that interferes with daily activities.

Radiomics: The extraction and analysis of high-dimensional quantitative features from medical images to characterise tissue heterogeneity and pathology.

Diffusion tensor imaging (DTI): An MRI technique that maps the diffusion of water molecules in white matter tracts, yielding metrics such as fractional anisotropy and mean diffusivity.

Machine learning (ML): A set of computational methods that enable algorithms to learn patterns from data and make predictions or classifications on new inputs.

Area under the curve (AUC): A performance metric for binary classifiers, representing the probability that the model ranks a randomly chosen positive instance higher than a negative one.

References

1. An interpretable multiparametric radiomics model of basal ganglia to predict dementia conversion in Parkinson’s disease. npj Parkinson's Disease (2023).
2. Detection of mild cognitive impairment in Parkinson’s disease using gradient boosting decision tree models based on multilevel DTI indices. Journal of Translational Medicine (2023).
3. Prediction of cognitive decline in Parkinson's disease based on MRI radiomics and clinical features: A multicenter study. CNS Neuroscience & Therapeutics (2024).
4. Prevalence and Subtypes of Mild Cognitive Impairment in Parkinson’s Disease. Scientific Reports (2016).
5. Cognition Deficits in Parkinson’s Disease: Mechanisms and Treatment. Parkinson's Disease (2020).
6. Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors. Behavioral Sciences (2021).
7. Cognitive decline in Parkinson’s disease: the complex picture. npj Parkinson's Disease (2016).
8. Parkinson’s Disease and Cognitive Impairment. Parkinson's Disease (2016).